
Zoetis (ZTS) Stock Forecast & Price Target
Zoetis (ZTS) Analyst Ratings
Bulls say
Zoetis demonstrates a positive outlook through significant investments in pet owner relationships, as evidenced by the increase in enrollment in the Zoetis Petcare Rewards program to 2.5 million users, up from 708,000 in 2018, alongside over $120 million allocated towards marketing in 2023. The company's revenue from key products such as Simparica, which generated $356 million in the third quarter, highlights a year-over-year growth of 7%, underscoring its strong market position in the companion animal sector. Additionally, core dermatological products have shown resilience, achieving $469 million in global revenue with a 3% year-over-year increase, further solidifying Zoetis's dominant presence in the animal health market.
Bears say
Zoetis has revised its 2025 revenue guidance downward to a range of $9.400 billion to $9.475 billion, reflecting diminished organic operational growth expectations, which indicates potential difficulties in maintaining growth momentum. The company's pain management segment experienced a significant 11% year-over-year decline due to safety concerns surrounding one of its products, impacting sales in a critical area. Additionally, the company's recent earnings report revealed a troubling stagnation in the U.S. companion animal health segment, attributed to increased competition and a drop in veterinary clinic visits, raising concerns about the sustainability of its revenue foundations.
This aggregate rating is based on analysts' research of Zoetis and is not a guaranteed prediction by Public.com or investment advice.
Zoetis (ZTS) Analyst Forecast & Price Prediction
Start investing in Zoetis (ZTS)
Order type
Buy in
Order amount
Est. shares
0 shares